Singapore's Qritive drives AI adoption in pathology and diagnosis across India

06 February 2024 | News

Qritive secures multi-year contracts with Metropolis Healthcare Limited, C?RE Diagnostics and Rajiv GandhiCancer Institute to Drive AI Adoption in Pathology Across India

Singapore headquartered Qritive^{TM}, a leading provider of AI solutions for pathology labs worldwide, has partnered with three esteemed diagnostic centres and hospitals in India: Metropolis Healthcare, Rajiv Gandhi Cancer Institute, and C?RE Diagnostics. The integration of Qritive's AI technology into the diagnostic processes of these institutions will leverage the power of artificial intelligence, these institutions are enhancing diagnostic accuracy, improving operational efficiency, and ultimately advancing patient care.

The three institutions have embraced Pantheon^{TM} image management system (IMS) and Qritive's AI products, marking them as trailblazers in the adoption of artificial intelligence in pathology workflows. The milestone represents a significant leap forward in the modernisation of pathology practices in India

The implementation of Qritive's AI-powered platform significantly transforms pathology workflows. Clinical studies carried out at prominent healthcare institutions reveal up to 90% reduction in the time needed for diagnoses and up to 80% decrease in discordance among pathologists. Such improvements lead to increased diagnostic accuracy and an overall enhancement in the quality of care for cancer patients.

Surendran Chemmenkottil, CEO, of Metropolis Healthcare, stated: "As we embark on this transformative journey with Qritive, we are enthusiastic about the immense potential it holds for advancing our capabilities in pathology. The integration of Qritive's AI-powered platform into our workflows signifies a revolutionary step in enhancing precision, timeliness, and personalised diagnosis. This collaboration reinforces our commitment to setting a new standard in cancer care, particularly in supporting clinicians in making effective treatment decisions for prostate cancer detection."

"Qritive is seizing the power of AI to improve patient outcomes and concurrently enhance the life of their pathologists. We are eager to showcase how deep tech will support clinicians and contribute to "closing the gap" in cancer care, meeting the aspirations of the World Cancer Day of 4th February." said Bruno Occhipinti, CEO of Qritive.

"By partnering with Qritive, integrating their advanced AI solutions into our pathology workflow at C?RE Diagnostics. This collaboration will strengthen our diagnostic precision, resulting in improved patient outcomes, and reaffirm our dedication to

delivering excellence in clinical care. The collaboration also has the potential to lead to the development of new AI services for the diagnosis of rare diseases." said Dinesh Chauhan, CEO of C?RE Diagnostics.

"Qritive's IMS and AI modules have enhanced our pathology practice at RGCI. With efficient identification of concerning areas and precise grading, integrating these tools has enhanced our workflow and diagnostic precision, offering significant benefits to our practice" says Dr Gurudutt Gupta, HOD Pathology at Rajiv Gandhi Cancer Institute Research Centre.